APA (7th ed.) Citation

Corbacioglu, S., Lode, H., Ellinger, S., Zeman, F., Suttorp, M., Escherich, G., . . . Greil, J. (2024). Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): A multicentre, open-label, randomised, controlled, phase 2 trial. The lancet. Oncology, 25(7), . https://doi.org/10.1016/S1470-2045(24)00202-X

Chicago Style (17th ed.) Citation

Corbacioglu, Selim, Holger Lode, Susanne Ellinger, Florian Zeman, Meinolf Suttorp, Gabriele Escherich, Toralf Bernig, and Johann Greil. "Irinotecan and Temozolomide in Combination with Dasatinib and Rapamycin Versus Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma (RIST-rNB-2011): A Multicentre, Open-label, Randomised, Controlled, Phase 2 Trial." The Lancet. Oncology 25, no. 7 (2024). https://doi.org/10.1016/S1470-2045(24)00202-X.

MLA (9th ed.) Citation

Corbacioglu, Selim, et al. "Irinotecan and Temozolomide in Combination with Dasatinib and Rapamycin Versus Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma (RIST-rNB-2011): A Multicentre, Open-label, Randomised, Controlled, Phase 2 Trial." The Lancet. Oncology, vol. 25, no. 7, 2024, https://doi.org/10.1016/S1470-2045(24)00202-X.